bluebird bio Future Growth
Future criteria checks 2/6
bluebird bio is forecast to grow earnings and revenue by 27.4% and 40.6% per annum respectively. EPS is expected to grow by 36% per annum. Return on equity is forecast to be -115.2% in 3 years.
Key information
27.4%
Earnings growth rate
36.0%
EPS growth rate
Biotechs earnings growth | 21.1% |
Revenue growth rate | 40.6% |
Future return on equity | -115.2% |
Analyst coverage | Good |
Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval
Feb 07bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success
Dec 12bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely
Nov 08bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
Nov 03Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 301 | -108 | N/A | N/A | 4 |
12/31/2025 | 258 | -155 | -235 | -201 | 12 |
12/31/2024 | 125 | -236 | -323 | -288 | 13 |
12/31/2023 | 37 | -199 | -327 | -270 | 12 |
9/30/2023 | 22 | -91 | -286 | -277 | N/A |
6/30/2023 | 9 | -96 | -301 | -293 | N/A |
3/31/2023 | 4 | -123 | -328 | -314 | N/A |
12/31/2022 | 4 | -267 | -366 | -353 | N/A |
9/30/2022 | 5 | -431 | -447 | -436 | N/A |
6/30/2022 | 6 | -507 | -525 | -506 | N/A |
3/31/2022 | 5 | -563 | -574 | -558 | N/A |
12/31/2021 | 4 | -563 | -659 | -636 | N/A |
9/30/2021 | -238 | -573 | -680 | -651 | N/A |
6/30/2021 | -220 | -614 | -678 | -653 | N/A |
3/31/2021 | -21 | -480 | -493 | -468 | N/A |
12/31/2020 | N/A | -561 | -499 | -470 | N/A |
9/30/2020 | 250 | -642 | -509 | -474 | N/A |
6/30/2020 | 240 | -653 | -493 | -439 | N/A |
3/31/2020 | 54 | -828 | -684 | -616 | N/A |
12/31/2019 | N/A | -555 | -641 | -564 | N/A |
9/30/2019 | 54 | -715 | -611 | -535 | N/A |
6/30/2019 | 57 | -655 | -569 | -496 | N/A |
3/31/2019 | 51 | -605 | -526 | -459 | N/A |
12/31/2018 | 55 | -556 | -469 | -413 | N/A |
9/30/2018 | 40 | -524 | -441 | -379 | N/A |
6/30/2018 | 36 | -457 | -404 | -361 | N/A |
3/31/2018 | 45 | -382 | -358 | -314 | N/A |
12/31/2017 | 35 | -336 | -343 | -281 | N/A |
9/30/2017 | 33 | -290 | -311 | -254 | N/A |
6/30/2017 | 27 | -288 | N/A | -237 | N/A |
3/31/2017 | 11 | -276 | N/A | -228 | N/A |
12/31/2016 | 6 | -264 | N/A | -190 | N/A |
9/30/2016 | 6 | -239 | N/A | -154 | N/A |
6/30/2016 | 6 | -205 | N/A | -143 | N/A |
3/31/2016 | 9 | -198 | N/A | -111 | N/A |
12/31/2015 | 14 | -167 | N/A | -98 | N/A |
9/30/2015 | 19 | -139 | N/A | -81 | N/A |
6/30/2015 | 24 | -113 | N/A | -73 | N/A |
3/31/2015 | 25 | -63 | N/A | -72 | N/A |
12/31/2014 | 25 | -49 | N/A | -60 | N/A |
9/30/2014 | 25 | -37 | N/A | -49 | N/A |
6/30/2014 | 25 | -26 | N/A | -38 | N/A |
3/31/2014 | 25 | -29 | N/A | -35 | N/A |
12/31/2013 | 20 | -25 | N/A | 43 | N/A |
9/30/2013 | 14 | -21 | N/A | 42 | N/A |
6/30/2013 | 8 | -15 | N/A | 47 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLUE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLUE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLUE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLUE's revenue (40.6% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: BLUE's revenue (40.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLUE is forecast to be unprofitable in 3 years.